Pfizer Inc (PFE)

33.86
0.54 1.60
NYSE : Health Care
Prev Close 33.32
Open 33.44
Day Low/High 33.40 / 34.02
52 Wk Low/High 28.25 / 37.39
Volume 28.53M
Avg Volume 18.95M
Exchange NYSE
Shares Outstanding 6.07B
Market Cap 206.17B
EPS 1.10
P/E Ratio 15.31
Div & Yield 1.20 (3.50%)

Latest News

Pfizer Completes Acquisition Of Medivation

Pfizer Completes Acquisition Of Medivation

Pfizer Inc. (NYSE: PFE) today announced the successful completion of its acquisition of Medivation, Inc.

Pfizer To Showcase Progress Of Broad-Based Oncology Portfolio At European Society For Medical Oncology (ESMO) 2016 Congress

Pfizer To Showcase Progress Of Broad-Based Oncology Portfolio At European Society For Medical Oncology (ESMO) 2016 Congress

Pfizer Inc. (NYSE:PFE) today announced that it will be presenting data from 20 abstracts, including three late-breakers, at the European Society for Medical Oncology (ESMO) 2016 Congress in Copenhagen from October 7-11,...

Wall Street Sells Off on Worries Over Clinton-Trump Showdown

Wall Street Sells Off on Worries Over Clinton-Trump Showdown

Stocks end Monday's session sharply lower as Wall Street grows restless ahead of the first presidential debate.

Stocks Fall Ahead of Clinton-Trump Debate, Crude Rallies

Stocks Fall Ahead of Clinton-Trump Debate, Crude Rallies

Stocks hold near session lows by mid-afternoon Monday as Wall Street grows restless ahead of the first presidential debate.

Read Scraps Pfizer Break-Up as Megadeals Escape Its Grasp

Read Scraps Pfizer Break-Up as Megadeals Escape Its Grasp

The company has spent $600 million weighing a potential breakup.

Pfizer (PFE) Stock Declines, Bernstein: More Deals Seem Likely

Pfizer (PFE) Stock Declines, Bernstein: More Deals Seem Likely

Bernstein analysts say Pfizer (PFE) is likely to continue seeking M&As following the end of its planned business split.

For Pain Therapeutics CEO, 3 FDA Rejections Are Worth $23 Million

For Pain Therapeutics CEO, 3 FDA Rejections Are Worth $23 Million

Failure is very profitable for Pain Therapeutics CEO Remi Barbier.

Stocks Fall as Health Care Slumps Ahead of Presidential Debate

Stocks Fall as Health Care Slumps Ahead of Presidential Debate

Stocks are lower Monday as Wall Street's attention shifts to the looming presidential debate from central bank policy.

Pfizer Decides Not to Split Business

Pfizer Decides Not to Split Business

Shares of Pfizer were lower Monday after saying it will no longer pursue its plan to split into two publicly traded companies.

Pfizer Nixes Business Split, Despite Activist Pressure

The company now believes that it makes more sense to keep its established drug and clinical products businesses under one roof.

U.S. Stocks Slip Ahead of Presidential Debate; Deutsche Bank Shares Plunge

U.S. Stocks Slip Ahead of Presidential Debate; Deutsche Bank Shares Plunge

U.S. stocks moved lower ahead of Monday's first presidential debate between Donald Trump and Hillary Clinton.

Stock Futures Fall With Clinton-Trump Showdown Looming

Stock Futures Fall With Clinton-Trump Showdown Looming

Stock futures fall on Monday as Wall Street's attention shifts from central bank policy to the looming presidential debate.

Pfizer (PFE) Stock Falls, Ends Plan to Split Into Two Companies

Pfizer (PFE) Stock Falls, Ends Plan to Split Into Two Companies

Pfizer (PFE) is abandoning a plan to split Pfizer Innovative Health and Pfizer Essential Health into two publicly traded companies.

Pfizer Decides Remaining One Company Best Positions Company To Maximize Future Value Creation

Pfizer Decides Remaining One Company Best Positions Company To Maximize Future Value Creation

Pfizer Inc. (NYSE:PFE) announced that, after an extensive evaluation, the company's Board of Directors and Executive Leadership Team have determined the company is best positioned to maximize future shareholder value...

Takeover Chatter Around Clovis May Be Overdone

Takeover Chatter Around Clovis May Be Overdone

Rumors are swirling about Big Pharma interest in the cancer drug developer, but the validity of such theories is questioned by at least some company followers.

Pfizer Announces Expiration Of HSR Waiting Period For Proposed Acquisition Of Medivation

Pfizer Announces Expiration Of HSR Waiting Period For Proposed Acquisition Of Medivation

Pfizer Inc. (NYSE: PFE) today announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended has expired with respect to Pfizer's pending acquisition of Medivation, Inc.

Pfizer Declares 30-Cent Fourth-Quarter 2016 Dividend

Pfizer Declares 30-Cent Fourth-Quarter 2016 Dividend

The board of directors of Pfizer Inc. today declared a 30-cent fourth-quarter 2016 dividend on the company's common stock, payable December 1, 2016, to shareholders of record at the close of business on November 11, 2016.

New Setback for Sanofi's Lantus Increases Need for M&A

New Setback for Sanofi's Lantus Increases Need for M&A

UnitedHealth becomes the second major healthcare provider to scratch the insulin product from its 2017 medicines roster.

Pfizer Invites Public To View And Listen To Webcast Of November 1 Conference Call With Analysts

Pfizer Invites Public To View And Listen To Webcast Of November 1 Conference Call With Analysts

Pfizer Inc. invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10 a.

Pull Those Stocks Up!

The market is just plain droopy.

Pfizer Announces Positive Top-Line Results From REFLECTIONS B537-02 Study For PF-06438179 (infliximab-Pfizer) A Potential Biosimilar To Remicade® (infliximab)

Pfizer Announces Positive Top-Line Results From REFLECTIONS B537-02 Study For PF-06438179 (infliximab-Pfizer) A Potential Biosimilar To Remicade® (infliximab)

Pfizer Inc. (NYSE:PFE) announced the confirmatory study (REFLECTIONS B537-02) evaluating the efficacy, safety, and immunogenicity of PF-06438179 (infliximab-Pfizer) compared to Remicade® (infliximab) met its primary...

Cempra Is Ready to Run

Cempra Is Ready to Run

Given predictable upcoming catalysts and a large addressable market, this small-cap biotech is a buy.

Pfizer Receives Positive CHMP Opinion For IBRANCE® (palbociclib) In Combination With Endocrine Therapy For The Treatment Of HR+/HER2- Metastatic Breast Cancer In Europe

Pfizer Receives Positive CHMP Opinion For IBRANCE® (palbociclib) In Combination With Endocrine Therapy For The Treatment Of HR+/HER2- Metastatic Breast Cancer In Europe

Pfizer Inc. (NYSE:PFE) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending that IBRANCE ® (palbociclib) be...

Bought Aerie Earlier? Congratulations

Bought Aerie Earlier? Congratulations

An update on some recent small biotech recommendations.

Good News on Pfizer and Sonoco Products

FDA announcements and a price increase should be beneficial to these portfolio names.

Pfizer's (PFE) Chantix Warning Could Be Removed After FDA Recommendation

Pfizer's (PFE) Chantix Warning Could Be Removed After FDA Recommendation

Two FDA panels have recommended that it's most serious warning label be removed from the Pfizer (PFE) drug Chantix.

Merck And Pfizer Announce Investigational Ertugliflozin Met Primary Endpoint Of A1C Reduction When Added To Sitagliptin And Metformin In People With Type 2 Diabetes

Merck And Pfizer Announce Investigational Ertugliflozin Met Primary Endpoint Of A1C Reduction When Added To Sitagliptin And Metformin In People With Type 2 Diabetes

Merck (NYSE: MRK), known as MSD outside the United States and Canada, in partnership with Pfizer Inc.